T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
Balaji Venugopal,Manon Pillai,Thomas Powles,Philip Savage,Agnieszka Michael,Kate Fife,Bhupinder Klair,Valerie Perrot,Bernadett Szabados +8 more
TL;DR: In this article, the authors describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (aRCC) enrolled in the UK managed access programme.
Journal ArticleDOI
Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.
Thomas Powles,Ajjai Alva,Mustafa Ozguroglu,Peter H. O'Donnell,Yohann Loriot,Tibor Csőszi,Jacqueline Vuky,Rafael Morales-Barrera,Elizabeth R. Plimack,Nobuaki Matsubara,Yves Fradet,Lajos Géczi,Seyda Gunduz,Ronac Mamtani,Dean F. Bajorin,Chih Chin Liu,Kentaro Imai,Blanca Homet Moreno,Joaquim Bellmunt,Arjun Vasant Balar +19 more
TL;DR: This post hoc landmark analysis evaluated clinical outcomes by response at 9 wk to 1L pembro monotherapy in pts with advanced/unresectable or metastatic UC from the single-arm phase 2 KEYNOTE-052 and the randomized phase 3 KEYnote-361 trials and found that 1 L pem Bro monotherapy continues to show efficacy in advanced UC.
Journal ArticleDOI
CO68 Simulated mOS of Gemcitabine+Carboplatin ± Maintenance Avelumab Therapy or Enfortumab Vedotin + Pembrolizumab in First-Line Treatment of LA/mUC in Patients Ineligible for Cisplatin Using Disease Modeling
Matthew D. Galsky,Guru Sonpavde,Brian Bloudek,Mallory Farrar,Zsolt Hepp,Jennifer Timmons,Thomas Powles +6 more
Journal ArticleDOI
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
Joaquim Bellmunt,Jeanny B. Aragon-Ching,Miguel Angel Climent,Srikala S. Sridhar,Thomas Powles,P. Cislo,Elisabete Michelon,Alessandra di Pietro,Petros Grivas +8 more
TL;DR: In the phase 3 JAVELIN Bladder 100 trial (NCT02603432), patients with aUC without progression after 1L platinum-based chemotherapy had significantly prolonged overall survival and progression-free survival with avelumab 1L maintenance + best supportive care (BSC) vs BSC alone as discussed by the authors .
Journal ArticleDOI
DNA alterations in papillary renal cancer.
Francesca Jackson-Spence,C Ackerman,Bernadett Szabados,C. Toms,Agnė Jovaišaitė,R.W. Gunnell,Cristina Sáez,James Larkin,P. Patel,Begoña P. Valderrama,Alejo Rodriguez-Vida,Hilary Glen,Fiona C Thistlethwaite,Christy Ralph,Gopalakrishnan Srinivasan,M.J. Méndez-Vidal,Aleksandra Markovets,Ryan J. Hartmaier,Thomas Powles +18 more
TL;DR: In this paper , the authors explored the relationship between MET, PD-L1 and TMB in these tumours and the relevance of other biomarkers including PIK3CA, PTEN and KRAS.